New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:13 EDTATRS, ACTAntares Pharma reports Q4 EPS (4c), consensus (5c)
Antares Pharma (ATRS) reports Q4 revenue $4.75M, consensus $6.15M. The company said "Product revenue decreased in Q4 to $0.9M. The decrease in product revenues in Q4 was primarily due to a decrease in sales of oxybutynin gel 3% product to Actavis (ACT), as Actavis assumed all manufacturing of Gelnique 3% in 1Q13, as contracted.
News For ATRS;ACT From The Last 14 Days
Check below for free stories on ATRS;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 1, 2014
17:02 EDTACTActavis files to sell 843,085 ordinary shares
The offering is related to shares that may be issued upon the exercise of stock options granted under certain equity plans of Forest Laboratories to former employees or former directors of Forest.
July 23, 2014
10:02 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
07:02 EDTATRSAntares Pharma announces first patient dosed in QuickShot Phase 3 study
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use